ACHV
FDA says “not yet”
Achieve Life Sciences got the dreaded Complete Response Letter for cytisinicline, its investigational smoking-cessation pill. That’s FDA-speak for: close, but please fix the paperwork before we hand over the keys.
What tripped it up
The agency’s concerns weren’t about whether the drug works. Instead, the CRL pointed to:
- manufacturing issues tied to a former third-party facility
- incomplete final product labeling
In other words, the science got a thumbs-up vibe, but the operations side showed up wearing mismatched shoes.
Why investors should care
Achieve says it already shifted to Adare Pharma Solutions as its new U.S.-based manufacturing partner, completed tech transfer work, and made its first engineering batch. The company now plans to resubmit the NDA in the fourth quarter of 2026.
If all goes smoothly after that, Achieve is still talking about possible FDA approval in the first half of 2027. So this is a delay, not a full-on derailment — but delays can still sting when you’re betting on a binary biotech catalyst.
The bigger picture
The company is leaning hard on its Phase 3 data, which it says showed strong smoking-abstinence results through treatment and into week 24. Big picture: the thesis is still alive, but the timeline just got longer, and in biotech, time is money with extra stress on top.